Monitoring ATOS open interest helps you see where real money is positioned on Atossa Therapeutics Inc's options and which strikes are attracting the most commitment from traders. Atossa Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor ATOS options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising ATOS options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Atossa Therapeutics Inc to settle.
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc.
was founded in 2008 and is based in Seattle, Washington.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where ATOS open interest is concentrated. Our scanner maps Atossa Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Atossa Therapeutics Inc's options open interest as the signal it is, not as an afterthought.
